EBIT: Income before interest and taxes.
SELLAS Life Sciences Group, Inc. (SLS) had EBIT of $-28.27M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-26.86M |
|
-- |
|
-- |
|
$28.27M |
|
$-28.27M |
|
$1.41M |
|
$-26.86M |
|
$-26.86M |
|
$-26.86M |
|
$-26.86M |
|
$-26.86M |
|
$-26.86M |
|
|
EBIT |
$-28.27M |
$-28.27M |
|
109.05M |
|
109.05M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$75.21M |
|
-- |
|
$3.13M |
|
$78.34M |
|
$7.02M |
|
-- |
|
$0.46M |
|
$7.47M |
|
$70.87M |
|
$68.96M |
|
$70.87M |
|
153.10M |
|
| Cash Flow Statement Financials | |
$-28.39M |
|
-- |
|
$86.30M |
|
$13.99M |
|
$71.89M |
|
$57.91M |
|
$1.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-37.90% |
|
-38.96% |
|
-34.29% |
|
-37.90% |
|
$0.46 |
|
$-0.26 |
|
$-0.26 |
|